These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Versatile and precise gene-targeting strategies for functional studies in mammalian cell lines. Wassef M; Luscan A; Battistella A; Le Corre S; Li H; Wallace MR; Vidaud M; Margueron R Methods; 2017 May; 121-122():45-54. PubMed ID: 28499832 [TBL] [Abstract][Full Text] [Related]
6. Probing the structural dynamics of the CRISPR-Cas9 RNA-guided DNA-cleavage system by coarse-grained modeling. Zheng W Proteins; 2017 Feb; 85(2):342-353. PubMed ID: 27936513 [TBL] [Abstract][Full Text] [Related]
7. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9. Yang H; Patel DJ Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637 [TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9 in Genome Editing and Beyond. Wang H; La Russa M; Qi LS Annu Rev Biochem; 2016 Jun; 85():227-64. PubMed ID: 27145843 [TBL] [Abstract][Full Text] [Related]
9. [CRISPR/CAS9, the King of Genome Editing Tools]. Bannikov AV; Lavrov AV Mol Biol (Mosk); 2017; 51(4):582-594. PubMed ID: 28900076 [TBL] [Abstract][Full Text] [Related]
10. Methods for decoding Cas9 protospacer adjacent motif (PAM) sequences: A brief overview. Karvelis T; Gasiunas G; Siksnys V Methods; 2017 May; 121-122():3-8. PubMed ID: 28344037 [TBL] [Abstract][Full Text] [Related]
11. Targeted genome editing in human cells using CRISPR/Cas nucleases and truncated guide RNAs. Fu Y; Reyon D; Joung JK Methods Enzymol; 2014; 546():21-45. PubMed ID: 25398334 [TBL] [Abstract][Full Text] [Related]
12. CRISPR-Cas9 system-driven site-specific selection pressure on Herpes simplex virus genomes. Li Z; Bi Y; Xiao H; Sun L; Ren Y; Li Y; Chen C; Cun W Virus Res; 2018 Jan; 244():286-295. PubMed ID: 28279800 [TBL] [Abstract][Full Text] [Related]
13. Sequential Activation of Guide RNAs to Enable Successive CRISPR-Cas9 Activities. Clarke R; Terry AR; Pennington H; Hasty C; MacDougall MS; Regan M; Merrill BJ Mol Cell; 2021 Jan; 81(2):226-238.e5. PubMed ID: 33378644 [TBL] [Abstract][Full Text] [Related]
14. Target-dependent nickase activities of the CRISPR-Cas nucleases Cpf1 and Cas9. Fu BXH; Smith JD; Fuchs RT; Mabuchi M; Curcuru J; Robb GB; Fire AZ Nat Microbiol; 2019 May; 4(5):888-897. PubMed ID: 30833733 [TBL] [Abstract][Full Text] [Related]
15. Optimization of genome editing through CRISPR-Cas9 engineering. Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770 [TBL] [Abstract][Full Text] [Related]
16. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. Yang HC; Chen PJ Virus Res; 2018 Jan; 244():304-310. PubMed ID: 28627393 [TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas based antiviral strategies against HIV-1. Wang G; Zhao N; Berkhout B; Das AT Virus Res; 2018 Jan; 244():321-332. PubMed ID: 28760348 [TBL] [Abstract][Full Text] [Related]
19. mCAL: A New Approach for Versatile Multiplex Action of Cas9 Using One sgRNA and Loci Flanked by a Programmed Target Sequence. Finnigan GC; Thorner J G3 (Bethesda); 2016 Jul; 6(7):2147-56. PubMed ID: 27185399 [TBL] [Abstract][Full Text] [Related]
20. Molecular basis for the PAM expansion and fidelity enhancement of an evolved Cas9 nuclease. Chen W; Zhang H; Zhang Y; Wang Y; Gan J; Ji Q PLoS Biol; 2019 Oct; 17(10):e3000496. PubMed ID: 31603896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]